Absorption of Val-Tyr with in Vitro angiotensin I-converting enzyme inhibitory activity into the circulating blood system of mild hypertensive subjects

Toshiro Matsui, Kei Tamaya, Eiji Seki, Katsuhiro Osajima, Kiyoshi Matsumoto, Terukazu Kawasaki

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

The change in plasma level of dipeptide, Val-Tyr (VY), with in vitro angiotensin I-converting enzyme inhibitory activity was investigated after a single oral administration of a VY-drink at doses of 0, 6 or 12 mg given to mild hypertensive subjects. During this protocol for up to 24 h after the intake, patient/subject blood pressure (BP) was measured for a 15 min period at designated times (0, 1, 2, 4, 8, 24 h) with the individual supine. Based on the VY determination, the maximal increment of plasma VY level was observed over the second hour post-prandially (12 mg-dose; 2041±148 fmol/ml-plasma). In addition, the plasma VY level increased with the VY dosage. However, no marked BP change was observed with the increase of plasma VY level, suggesting that VY did not exert an acute hypotensive effect. The area under the curve at 12 mg-dose was estimated to be 8644±420 fmol·h/ml-plasma, comparable to that in normotensive subjects. This finding suggests that absorption of VY would not be influenced by a complaint of hypertension.

Original languageEnglish
Pages (from-to)1228-1230
Number of pages3
JournalBiological and Pharmaceutical Bulletin
Volume25
Issue number9
DOIs
Publication statusPublished - Sep 1 2002

Fingerprint

valyltyrosine
Peptidyl-Dipeptidase A
Blood Pressure
Dipeptides
Area Under Curve
Oral Administration
In Vitro Techniques
Hypertension

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Absorption of Val-Tyr with in Vitro angiotensin I-converting enzyme inhibitory activity into the circulating blood system of mild hypertensive subjects. / Matsui, Toshiro; Tamaya, Kei; Seki, Eiji; Osajima, Katsuhiro; Matsumoto, Kiyoshi; Kawasaki, Terukazu.

In: Biological and Pharmaceutical Bulletin, Vol. 25, No. 9, 01.09.2002, p. 1228-1230.

Research output: Contribution to journalArticle

Matsui, Toshiro ; Tamaya, Kei ; Seki, Eiji ; Osajima, Katsuhiro ; Matsumoto, Kiyoshi ; Kawasaki, Terukazu. / Absorption of Val-Tyr with in Vitro angiotensin I-converting enzyme inhibitory activity into the circulating blood system of mild hypertensive subjects. In: Biological and Pharmaceutical Bulletin. 2002 ; Vol. 25, No. 9. pp. 1228-1230.
@article{22eaea2dc30745eaae0be399f7894eb7,
title = "Absorption of Val-Tyr with in Vitro angiotensin I-converting enzyme inhibitory activity into the circulating blood system of mild hypertensive subjects",
abstract = "The change in plasma level of dipeptide, Val-Tyr (VY), with in vitro angiotensin I-converting enzyme inhibitory activity was investigated after a single oral administration of a VY-drink at doses of 0, 6 or 12 mg given to mild hypertensive subjects. During this protocol for up to 24 h after the intake, patient/subject blood pressure (BP) was measured for a 15 min period at designated times (0, 1, 2, 4, 8, 24 h) with the individual supine. Based on the VY determination, the maximal increment of plasma VY level was observed over the second hour post-prandially (12 mg-dose; 2041±148 fmol/ml-plasma). In addition, the plasma VY level increased with the VY dosage. However, no marked BP change was observed with the increase of plasma VY level, suggesting that VY did not exert an acute hypotensive effect. The area under the curve at 12 mg-dose was estimated to be 8644±420 fmol·h/ml-plasma, comparable to that in normotensive subjects. This finding suggests that absorption of VY would not be influenced by a complaint of hypertension.",
author = "Toshiro Matsui and Kei Tamaya and Eiji Seki and Katsuhiro Osajima and Kiyoshi Matsumoto and Terukazu Kawasaki",
year = "2002",
month = "9",
day = "1",
doi = "10.1248/bpb.25.1228",
language = "English",
volume = "25",
pages = "1228--1230",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "9",

}

TY - JOUR

T1 - Absorption of Val-Tyr with in Vitro angiotensin I-converting enzyme inhibitory activity into the circulating blood system of mild hypertensive subjects

AU - Matsui, Toshiro

AU - Tamaya, Kei

AU - Seki, Eiji

AU - Osajima, Katsuhiro

AU - Matsumoto, Kiyoshi

AU - Kawasaki, Terukazu

PY - 2002/9/1

Y1 - 2002/9/1

N2 - The change in plasma level of dipeptide, Val-Tyr (VY), with in vitro angiotensin I-converting enzyme inhibitory activity was investigated after a single oral administration of a VY-drink at doses of 0, 6 or 12 mg given to mild hypertensive subjects. During this protocol for up to 24 h after the intake, patient/subject blood pressure (BP) was measured for a 15 min period at designated times (0, 1, 2, 4, 8, 24 h) with the individual supine. Based on the VY determination, the maximal increment of plasma VY level was observed over the second hour post-prandially (12 mg-dose; 2041±148 fmol/ml-plasma). In addition, the plasma VY level increased with the VY dosage. However, no marked BP change was observed with the increase of plasma VY level, suggesting that VY did not exert an acute hypotensive effect. The area under the curve at 12 mg-dose was estimated to be 8644±420 fmol·h/ml-plasma, comparable to that in normotensive subjects. This finding suggests that absorption of VY would not be influenced by a complaint of hypertension.

AB - The change in plasma level of dipeptide, Val-Tyr (VY), with in vitro angiotensin I-converting enzyme inhibitory activity was investigated after a single oral administration of a VY-drink at doses of 0, 6 or 12 mg given to mild hypertensive subjects. During this protocol for up to 24 h after the intake, patient/subject blood pressure (BP) was measured for a 15 min period at designated times (0, 1, 2, 4, 8, 24 h) with the individual supine. Based on the VY determination, the maximal increment of plasma VY level was observed over the second hour post-prandially (12 mg-dose; 2041±148 fmol/ml-plasma). In addition, the plasma VY level increased with the VY dosage. However, no marked BP change was observed with the increase of plasma VY level, suggesting that VY did not exert an acute hypotensive effect. The area under the curve at 12 mg-dose was estimated to be 8644±420 fmol·h/ml-plasma, comparable to that in normotensive subjects. This finding suggests that absorption of VY would not be influenced by a complaint of hypertension.

UR - http://www.scopus.com/inward/record.url?scp=0036726623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036726623&partnerID=8YFLogxK

U2 - 10.1248/bpb.25.1228

DO - 10.1248/bpb.25.1228

M3 - Article

C2 - 12230125

AN - SCOPUS:0036726623

VL - 25

SP - 1228

EP - 1230

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 9

ER -